Skip to content

Geron GERN Accrued liabilities

Accrued liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$3.5B-457%
Celcuity logo
CelcuityCELC

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's accrued liabilities?
Geron (GERN) reported accrued liabilities of -$20.37M in Q1 2026.
How has Geron's accrued liabilities changed year-over-year?
Geron's accrued liabilities decreased by 205.8% year-over-year, from -$6.66M to -$20.37M.
What is the long-term trend for Geron's accrued liabilities?
Over 3 years (2021 to 2024), Geron's accrued liabilities has grown at a -31.7% compound annual growth rate (CAGR), from $14.91M to -$4.76M.